In response to the COVID-19 pandemic, the European Society of Medical Oncology has published recommendations for the management of patients with lung cancer to maintain high-quality standards of treatment.
The FDA granted Breakthrough Therapy designation to osimertinib as adjuvant treatment of patients with stage IB-IIIA EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.
In an interview with Targeted Oncology, Delvys Rodriguez-Abreu, MD, discussed the findings from the KEYNOTE-189, which established the combination of pembrolizumab plus pemetrexed and platinum chemotherapy as the new standard of care for patients with metastatic nonsquamous non-small cell lung cancer.
A nationwide group of clinical investigators teamed up to explore options on how to manage patients with locally advanced non-small cell lung cancer in a multidisciplinary setting during the ongoing pandemic of coronavirus disease 2019.
In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discussed the results of the phase II VISION study, which evaluated tepotinib in patients with advanced non-small cell lung cancer and harbor the MET exon 14 skipping mutation. She also highlighted the role of liquid biopsy in this space.
Broad adoption of testing methods that allow for assessing all possible actionable targets and diagnostic markers in advanced cancer is becoming more complex with greater availability of lifesaving targeted therapies.